Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease by Luukkonen, Panu K. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/89700/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Luukkonen, Panu K., Zhou, You, Sädevirta, Sanja, Leivonen, Marja, Arola, Johanna, Orešič, Matej,
Hyötyläinen, Tuulia and Yki­Järvinen, Hannele 2016. Hepatic ceramides dissociate steatosis and
insulin resistance in patients with non­alcoholic fatty liver disease. Journal of Hepatology 64 (5) ,
pp. 1167­1175. 10.1016/j.jhep.2016.01.002 filefile 
Publishers page: http://dx.doi.org/10.1016/j.jhep.2016.01.002
<http://dx.doi.org/10.1016/j.jhep.2016.01.002>
Please note: 
Changes made as a result of publishing processes such as copy­editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1 
Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in 
Non-Alcoholic Fatty Liver Disease 
Short title: Ceramides in Human Non-Alcoholic Fatty Liver Disease 
Panu K. Luukkonen
1, 2*
, You Zhou
1*
, Sanja Sädevirta
1, 2
, Marja Leivonen
3
, Johanna 
Arola
4
, Matej Orešič5, Tuulia Hyötyläinen5, Hannele Yki-Järvinen1, 2 
1
Minerva Foundation Institute for Medical Research, Helsinki, Finland, 
2
Department 
of Medicine, 
3
Department of Surgery and 
4
Department of Pathology, University of 
Helsinki and Helsinki University Hospital, Helsinki, Finland, 
5
Steno Diabetes Center, 
Gentofte, Denmark 
*These authors contributed equally to this work 
GRANT SUPPORT: This study was supported by research grants from the Academy 
of Finland (HY), EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF 
grant no. 115372, HY), the Sigrid Juselius (HY), EVO (HY) and the Novo Nordisk 
(HY) Foundations. The authors are members of the EPoS (Elucidating Pathways of 
Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the 
European Union under Grant Agreement 634413.
*Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
ABBREVIATIONS: 
ALP   alkaline phosphatase 
ALT   alanine aminotransferase 
AST   aspartate aminotransferase 
BMI   body mass index 
CoA   coenzyme A 
DAG    diacylglycerol 
DNL   de novo lipogenesis 
FFA   free fatty acid 
GGT   gamma-glutamyl transferase 
HDL   high density lipoprotein 
HOMA-IR  homeostasis model assessment of insulin resistance 
IR   insulin resistance 
NAFLD  non-alcoholic fatty liver disease 
NASH   non-alcoholic steatohepatitis 
OGTT   oral glucose tolerance test 
PNPLA3  patatin-like phospholipase domain containing protein 3 
TAG   triacylglycerol 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
CORRESPONDING AUTHOR:
Panu K. Luukkonen, MD,  
Tukholmankatu 8 
00290 Helsinki 
FINLAND 
E-mail: panu.luukkonen@fimnet.fi 
Phone: +358 294125708 
DISCLOSURES: None. 
ELECTRONIC WORD COUNT: 5989 words. 
FIGURES: 5 
TABLES: 1 
AUTHOR CONTRIBUTIONS: PL – study concept and design; acquisition of data; 
analysis and interpretation of data; drafting of the manuscript; critical revision of the 
manuscript for important intellectual content; statistical analysis. YZ – study concept 
and design; analysis and interpretation of data; drafting of the manuscript; critical 
revision of the manuscript for important intellectual content; statistical analysis. SS, 
ML, JA, MO, TH – acquisition of data; critical revision of the manuscript for 
important intellectual content. HY – study concept and design; analysis and 
interpretation of data; drafting of the manuscript; critical revision of the manuscript 
for important intellectual content; obtained funding; study supervision. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
ABSTRACT: 
Background and Aims: Recent data in mice have identified de novo ceramide 
synthesis as the key mediator of hepatic insulin resistance (IR) that in humans 
characterizes increases in liver fat due to IR (‘Metabolic NAFLD’ but not that due to 
the I148M gene variant in PNPLA3 (‘PNPLA3 NAFLD’). We determined which 
bioactive lipids co-segregate with IR in the human liver.
Methods: Liver lipidome was profiled in liver biopsies from 125 subjects that were 
divided into equally sized groups based on median HOMA-IR (‘High and Low 
HOMA-IR’, n=62 and n=63) or PNPLA3 genotype (PNPLA3148MM/MI, n=61 vs. 
PNPLA3
148II
, n=64). The subjects were also divided into 4 groups who had either IR,
the I148M gene variant, both of the risk factors or neither.
Results: Steatosis and NASH prevalence were similarly increased in ‘High HOMA-
IR’ and PNPLA3148MM/MI groups compared to their respective control groups. The 
‘High HOMA-IR’ but not the PNPLA3148MM/MI group had features of IR. The liver in 
‘High HOMA-IR’ vs. ‘Low HOMA-IR’ was markedly enriched in saturated and 
monounsaturated triacylglycerols and free fatty acids, dihydroceramides (markers of 
de novo ceramide synthesis) and ceramides. Markers of other ceramide synthetic 
pathways were unchanged. In PNPLA3
148MM/MI
 vs. PNPLA3
148II
, the increase in liver 
fat was due to polyunsaturated triacylglycerols while other lipids were unchanged.
Similar changes were observed when data were analyzed using the 4 subgroups.
Conclusions: Similar increases in liver fat and NASH are associated with a 
metabolically harmful saturated, ceramide-enriched liver lipidome in ‘Metabolic 
NAFLD’ but not in ‘PNPLA3 NAFLD’. This difference may explain why metabolic 
but not PNPLA3 NAFLD increases the risk of type 2 diabetes and CVD.
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KEYWORDS: Patatin-like phospholipase domain containing protein 3 
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Introduction 
Both features of the metabolic syndrome and non-alcoholic fatty liver disease 
(NAFLD) predict type 2 diabetes and cardiovascular disease even independent of 
obesity in several prospective studies [1]. Such a form of NAFLD  (‘Metabolic 
NAFLD’) is characterized by hepatic insulin resistance (IR) [2,3], increased serum 
triacylglycerols (TAG), low HDL cholesterol and low serum adiponectin 
concentrations [4]. The latter may reflect adipose tissue inflammation [5,6]. 
’Metabolic NAFLD’ precedes and predicts type 2 diabetes and CVD [1].
In insulin-resistant ‘Metabolic NAFLD’, studies tracing pathways contributing to 
intrahepatocellular TAGs have shown that increased hepatic de novo lipogenesis 
(DNL) is the major cause for increased intrahepatocellular TAG content in ‘Metabolic 
NAFLD’[7]. DNL produces exclusively saturated fatty acids, which can be 
desaturated to form monounsaturated fatty acids by SCD-1 [8,9]. A hepatic venous 
catheterization study showed that fatty liver overproduces saturated TAGs [10].  
At least two classes of bioactive lipids, ceramides and diacylglycerols (DAGs), have 
been suggested to mediate insulin resistance. The ‘ceramide-centric’ view postulates 
both saturated fat from DNL or from the diet and adiponectin deficiency induce IR via 
increasing ceramide synthesis [11]. Ceramides also induce ER stress and 
mitochondrial dysfunction, which characterize human NAFLD [12]. The immediate 
precursors of TAGs, DAGs induce IR by inhibiting PI3-kinase and Akt/protein kinase 
B activation via stimulation of protein kinase C isoforms [13].  
Ceramides can be synthesized via the de novo synthetic pathway from palmitate, via 
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7 
sphingomyelin hydrolysis and via the salvage pathway, which uses hexosylceramides 
as its substrate [11]. Two very recent studies in mice identified the same sphingolipid 
species, C16:0-ceramide, formed via ceramide synthase 6, in the de novo ceramide 
synthetic pathway as the principal mediator of obesity-related insulin resistance [14-
16]. There are no human data to examine which if any of these pathways contributes 
to changes in ceramide concentrations in the human liver. 
A common I148M variant in PNPLA3 at rs738409 increases liver fat content [17]. 
Depending on ethnicity, 20-50% of all subjects carry this gene variant [17]. In vitro, 
this gene variant inhibits lipolysis of TAGs in the liver [18] and acts as a gain-of-
function mutation to increase TAG synthesis by acting as a lysophosphatidic 
acyltransferase (LPAAT) converting lysophosphatidic acid into phosphatitidic acid 
[19]. Monounsaturated fatty acid containing acyl CoAs such as oleyl CoA are 
preferred substrates for the former activity while polyunsaturated fatty acyl CoAs 
such as linoleoyl and arachidonoyl CoA are preferred substrates for the latter activity 
[18,19]. In contrast to the metabolic abnormalities observed in ’Metabolic NAFLD’, 
NAFLD due to the I148M variant (‘PNPLA3 NAFLD’) is not characterized by 
features of insulin resistance such as adipose tissue inflammation, adiponectin 
deficiency or an increased risk of type 2 diabetes and CVD [20,21].  
‘Metabolic NAFLD’ and ’PNPLA3 NAFLD’ provide models to characterize how 
insulin resistance and steatosis dissociate in the human liver. Given the high 
prevalence of both the metabolic syndrome and the I148M PNPLA3 gene variant, 
some individuals will have both of these risk factors for NAFLD. In the present study, 
we hypothesized that the liver in ’Metabolic NAFLD’ might be characterized by 
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increased concentrations of saturated/monounsaturated TAGs, free fatty acids (FFA) 
and IR-inducing bioactive lipids, while such metabolically harmful lipids may not be 
found in ’PNPLA3 NAFLD’. To this end, we analyzed the human liver lipidome in 
125 liver biopsy samples using ultra high performance liquid chromatography 
(UHPLC) and gas chromatography combined with mass spectrometry (MS). This was 
done in groups divided based on median HOMA-IR into those with ’High HOMA-IR’ 
(a model for ’Metabolic NAFLD’) and ‘Low HOMA-IR’, and based on genotyping at 
rs738409 into carriers (PNPLA3
148MM/MI) (a model for ’PNPLA3 NAFLD’) and non-
carriers (PNPLA3
148II
) of the PNPLA3 I148M gene variant. We also compared liver 
lipidomes in 4 groups of subjects who had both IR and carried the I148M gene variant 
(‘double trouble’), either (‘single trouble’) or neither risk factor.
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Materials and methods 
Study subjects  
A total of 125 subjects were recruited amongst those undergoing laparoscopic 
bariatric surgery. Subjects were eligible if they met the following criteria: (a) age 18 
to 75 years; (b) no known acute or chronic disease except for obesity or type 2 
diabetes or hypertension on the basis of medical history, physical examination and 
standard laboratory tests (complete blood count, serum creatinine, electrolyte 
concentrations); (c) alcohol consumption less than 20 g per day for women and less 
than 30 g per day for men; (d) no clinical or biochemical evidence of other liver 
disease, or clinical signs or symptoms of inborn errors of metabolism; (e) no history 
of use of toxins or drugs associated with liver steatosis. Elevated liver enzymes (ALT 
and AST) were not exclusion criteria. The study protocol was approved by the ethics 
committee of the Hospital District of Helsinki and Uusimaa. The study was conducted 
in accordance with the Declaration of Helsinki. Each participant provided written 
informed consent after being explained the nature and potential risks of the study. 
Metabolic study 
The subjects were invited to a separate clinical visit one week prior to surgery for 
detailed metabolic characterization. The subjects came to the clinical research center 
after an overnight fast. Body weight, height and waist circumference were measured 
as described [21]. An intravenous cannula was inserted in the antecubital vein for 
withdrawal of blood for measurement of HbA1c, serum insulin and adiponectin, 
plasma glucose, LDL- and HDL-cholesterol, triglyceride, albumin, AST, ALT, ALP 
and GGT concentrations and for genotyping as described [21]. Plasma albumin was 
measured using a photometric method on an autoanalyzer (Modular Analytics EVO; 
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10 
Hitachi High-Technologies Corporation, Tokyo, Japan). PNPLA3 at rs739409 was 
genotyped as previously described [22]. After basal blood sampling and 
anthropometric measurements, an oral glucose (75 grams) tolerance test (OGTT) was 
performed [23]. Homeostasis model assessment of insulin resistance (HOMA-IR) was 
used as a proxy for IR by using the formula: HOMA-IR = fS-insulin (mU/l) x fP-
glucose (mmol/l) / 22.5 [24]. Matsuda insulin sensitivity index was used as another 
measure of insulin sensitivity. This measure was calculated from insulin and glucose 
concentrations measured at 0, 30 and 120 minutes during the OGTT [25]. Body 
weight of the subjects was similar at the time of the metabolic study and surgery 
(131.1±2.0 and 130.1±2.1 kg, NS).  
The subjects (n=125) were divided into two groups based on insulin resistance, as 
defined by median HOMA-IR. Because of lack of universally accepted consensus 
regarding the cut-off threshold of HOMA-IR between the insulin-resistant and 
sensitive subjects, median HOMA-IR was used to divide the subjects into 'High 
HOMA-IR' (HOMA-IR > 3.19) and 'Low HOMA-IR' (HOMA-IR ≤ 3.19) groups. In 
retrospect, this cut-off was very similar to the HOMA-IR cut-off differentiating 
subjects with and without NASH (3.38) (see Supplementary Material). However, as 
the primary aim was to examine how risk factors (IR or the PNPLA3 gene variant) 
influenced the liver lipidome as well as other features including liver histology, we 
did not a priori divide the subjects into groups based on NASH.
Since some patients are both insulin resistant and carry the PNPLA3 gene variant, we 
also divided the subjects 2x2 based on both of these characteristics into 4 groups 
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11 
(Venn diagram as Supplementary Fig. 1 and other data as Supplementary Material p. 
11-13, Supplementary Figures 6-8 and Supplementary Table 2).
Liver biopsies and liver histology 
Immediately at the beginning of the surgery, wedge biopsies of the liver were 
obtained. Part of the biopsy was sent to the pathologist for histological assessment, 
and the rest was snap-frozen in liquid nitrogen for subsequent analysis of molecular 
lipids. The time from obtaining the biopsy until freezing the sample in liquid nitrogen 
was approximately one minute. Liver histology was analyzed by an experienced liver 
pathologist (J.A.) in a blinded fashion as proposed by Brunt et al [26].  
Lipidomic analysis 
The lipidome was analyzed using UHPLC-MS as described in Supplementary 
Material. The analyses covered most of the main molecular lipids, including 
ceramides, dihydroceramides, TAGs, DAGs, sphingomyelins, hexosylceramides, 
phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylserines 
(PS), and lysophosphosphatidylcholines. The lipid identification was based on an 
internal library, which had been constructed based on accurate mass measurements in 
combination with tandem mass measurements. For specific lipids, the composition of 
fatty acid chains had been determined with separate measurements, and for those the 
fatty acid composition was specified, e.g. TAG(14:0/16:0/18:0). 
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Cluster analysis of lipids 
We performed Bayesian model-based clustering analysis to identify the groups of 
lipids with similar profiles across all the samples as described in the Supplementary 
Material. 
Analysis of pathways of ceramide synthesis  
The first step of the de novo ceramide synthetic pathway converts palmitate and serine 
to 3-ketosphinganine and ultimately to dihydroceramides prior to formation of 
ceramides (Fig. 5). The sphingomyelin hydrolysis pathway results in formation of 
ceramides via hydrolysis of sphingomyelins. The salvage pathway generates 
ceramides by breakdown of complex sphingolipids, such as hexosylceramides (Fig. 5) 
[11]. In the present study, we analyzed the concentrations of dihydroceramides, 
sphingomyelins and hexosylceramides as markers of these pathways, respectively.  
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Analysis of hepatic free fatty acids  
The free fatty acid analyses were performed using GC-MS as described in the 
Supplementary Material. 
Statistical analyses 
Continuous variables were tested for normality using the Kolmogorov-Smirnov test. 
The independent two-sample Student t test and Mann-Whitney U test were used to 
compare normally and non-normally distributed data, respectively. Normally 
distributed data were reported in means ± standard error of means while non-normally 
distributed were reported in medians and interquartile ranges. Pearson’s χ2 test was 
used to evaluate if the distribution of categorical variables differ between the groups. 
Statistical analyses were performed by using R 3.1.1 (http://www.r-project.org/), IBM 
SPSS Statistics 22.0.0.0 version (IBM, Armonk, NY) and GraphPad Prism 6.0f for 
Mac OS X (GraphPad Software, La Jolla, CA). A two-sided p-value of less than 0.05 
indicated statistical significance.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
Results 
Characteristics of the study groups 
Characteristics of the HOMA-IR and PNPLA3 genotype subgroups are shown in 
Table 1. All groups were similar with respect to gender (Table 1) and BMI (Fig. 1).   
HOMA-IR subgroups 
Liver fat was significantly and 3-fold higher in the ‘High HOMA-IR’ (15 [5–33]) than 
in the ‘Low HOMA-IR’ group (5 [0–20], p<0.002, Fig. 1A). The ‘High HOMA-IR’ 
group had significantly higher fasting serum insulin concentrations than the ‘Low 
HOMA-IR’ group (Fig. 1A) and also higher glucose and insulin concentrations in the 
OGTT (Fig. 1B).
The ‘High HOMA-IR’ group had higher triglyceride and lower HDL cholesterol and 
adiponectin concentrations compared to the ‘Low HOMA-IR’ group (Table 1 and Fig. 
1A). The prevalence of NASH was significantly increased in the ‘High HOMA-IR’ as 
compared to the ‘Low HOMA-IR’ group (Table 1). The distributions of PNPLA3 
genotypes were similar in 'High HOMA-IR' and 'Low HOMA-IR' (Table 1).
Subgroups based on PNPLA3 genotype 
Liver fat was significantly and 3-fold higher in the ‘PNPLA3148MM/MI’ (15 [5–30]) 
than the ‘PNPLA3148II’ group (5 [0–28], p<0.04, Fig. 1A). Glucose and insulin 
concentrations, HOMA-IR, serum lipid and adiponectin concentrations were similar 
between the subgroups (Table 1 and Fig. 1A). The prevalence of NASH was 
significantly increased in the PNPLA3
148MM/MI
 as compared to the PNPLA3
148II
 group.
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Liver TAGs 
Saturated and monounsaturated TAGs were particularly enriched in ‘High HOMA-
IR’ as compared to the ‘Low HOMA-IR’ group. In contrast, these TAGs were similar 
between PNPLA3 subgroups (Fig. 2). The PNPLA3
148MM/MI 
compared to the 
PNPLA3
148II 
group displayed significant increases in polyunsaturated TAGs 
containing 3 to 11 double bonds (Fig. 2). Similar differences in TAGs between 
PNPLA3 subgroups were observed when this analysis was performed in ’Low 
HOMA-IR’ subjects alone (Supplementary Fig. 3). The number of double bonds in 
TAGs was inversely related to relative TAG concentrations between the ‘High’ as 
compared to ‘Low HOMA-IR’ group, but positively related between the PNPLA3 
subgroups (Supplementary Fig. 4). 
Liver FFAs
Hepatic concentrations of free palmitate (C16:0) (372 [296–502] vs 333 [279–402] 
nmol/g, p<0.05), stearate (C18:0) (202 [149–250] vs 164 [135–200], p<0.05) and 
oleate (C18:1) (188 [140–254] vs 164 [126– 207], p<0.05) were significantly higher 
in the ‘High HOMA-IR’ than the ‘Low HOMA-IR’ group. The polyunsaturated free 
linoleate (C18:2) and arachidonate (C20:4) were similar between the HOMA-IR 
subgroups (Fig. 3). Hepatic FFAs did not differ between the ‘PNPLA3148II’ and 
‘PNPLA3148MM/MI’ groups (Fig. 3).
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Liver ceramides 
Ceramide concentrations. Almost all ceramide species were significantly increased in 
the ‘High HOMA-IR’ as compared to the ‘Low HOMA-IR’ group while there were 
no change between the PNPLA3
148MM/MI 
and PNPLA3
148II
 groups (Fig. 4). This was 
also true when the PNPLA3 subgroups were compared within the ‘Low HOMA-IR’
group (Supplementary Fig. 3).
Pathways of ceramide synthesis. The hepatic concentrations of dihydroceramides 
(markers of de novo synthesis), sphingomyelins (markers of sphingomyelin 
hydrolysis) and hexosylceramides (markers of the salvage pathway) were analysed to 
determine which ceramide synthetic pathway was upregulated in the ‘High HOMA-
IR’ as compared to the ‘Low HOMA-IR’ group. Concentrations of 4 out of 5 
dihydroceramide species were significantly increased in ‘High’ as compared to ‘Low 
HOMA-IR’ group, while the concentrations of sphingomyelins and hexocylceramides 
were unchanged (Fig. 5).  In all subjects, there was an inverse relationship between 
serum adiponectin and total hepatic ceramides (r = -0.21, p = 0.022). 
Liver DAGs 
Four DAG species were significantly increased in the ‘High’ vs. the ‘Low HOMA-IR’ 
group, and one polyunsaturated species between the PNPLA3
148MM/MI
 vs. the 
PNPLA3
148II 
group (Supplementary Fig. 5). 
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Paired analyses of HOMA-IR and PNPLA3 with 4 groups
Subject characteristics of the 4 subgroups (High HOMA-IR and variant carrier i.e. 
PNPLA3
148MM/MI
, Low HOMA-IR and variant, High HOMA-IR and no variant, Low 
HOMA-IR and no variant) are shown in Supplementary Table 2, Supplementary Fig. 
6-8 and on page 11-13 of the Supplement.  
Insulin resistance (comparison of High HOMA-IR and Low HOMA-IR in subjects 
carrying the I148M gene variant) increased TAGs with no or few double bonds while 
the PNPLA3 gene variant (comparison of variant allele carriers and no carriers in 
subjects with similar HOMA-IR) increased polyunsaturated TAGs (Supplementary 
Fig. 7). Insulin resistance also increased almost all ceramides in the face of a similar 
genetic background while the I148M gene variant had no effect on ceramides in the 
face of similar HOMA-IR (Supplementary Fig. 8). 
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Discussion 
In the present study, we analyzed the human liver lipidome in two types of NAFLD, 
one defined based on IR (’Metabolic NAFLD’) and the other based on PNPLA3 
genotype at rs738409 (’PNPLA3 NAFLD’). Both types of NAFLD had a similar 
increase in % liver fat and NASH. The liver lipidome in ’Metabolic NAFLD’ was 
characterized by an increase in saturated and monounsaturated TAGs and FFA while 
the liver in ’PNPLA3 NAFLD’ predominantly contained an excess of polyunsaturated 
TAGs with no changes in FFA. The liver in ‘Metabolic NAFLD’ but not ‘PNPLA3 
NAFLD’ was markedly enriched in insulin-resistance inducing ceramides synthesized 
via the de novo ceramide synthetic pathway (Fig. 4). 
To define ‘Metabolic NAFLD’, we divided the subjects based on median HOMA-IR. 
We and others have previously performed direct measurements of insulin sensitivity 
and shown that fasting insulin concentrations as well as directly measured hepatic 
insulin sensitivity correlate with liver fat content [3,27]. There are no universally 
accepted criteria for IR using HOMA-IR. Since we wanted to examine how the 
etiology (insulin resistance or the PNPLA3 I148M variant or both) influences the liver 
lipidome and histology rather than vice versa, we divided the  subjects based on these 
characteristics rather than  histology. The median HOMA-IR (3.2), was comparable to 
the HOMA-IR value differentiating subjects with and without NASH (3.4). The use of 
median HOMA-IR also resulted in subgroups with an almost identical sample size, 
age, gender, BMI and similar increases in liver fat and NASH prevalence, thus 
enabling examination of effects of IR and effects of the PNPLA3 I148M gene variant 
on liver lipidome independently of confounders. To further dissect effects of insulin 
resistance and the gene variant on the liver lipidome, we also compared PNPLA3 
subgroups within the ‘Low HOMA-IR’ group (Fig. 3) and performed a 2x2 analysis 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
19 
where the subjects were grouped into those with ‘double trouble’ (both PNPLA3 
I148M gene variant and insulin resistance), ‘single trouble’ (either gene variant or 
insulin resistance), or neither. These additional analyses yielded results similar to 
those of grouping all subjects either based on the gene variant or HOMA-IR (Table 1, 
Fig. 1-4, Supplementary Table 2, Supplementary Fig. 6-8).
The PNPLA3 variant allele carriers as compared to the non-carriers had a 
significantly higher liver fat content and no features of insulin resistance as 
determined from HOMA-IR, serum lipids and adiponectin concentrations. Lack of IR 
was also verified by calculating the Matsuda index from glucose and insulin 
concentrations measured during the OGTT (Table 1) and is consistent with 13 out of 
15 previous studies showing no increased insulin resistance in ’PNPLA3 NAFLD’
[21]. Our  study cohort included 66 % women and 34 % men, which is not 
representative of epidemiologic studies, in which NAFLD is more prevalent in men 
than in women [28]. However, the gender distributions were comparable between all 
subgroups, and also in subjects with NASH.
The liver biopsies were taken after an overnight fast, when peripheral lipolysis and 
DNL are the main sources of fatty acids for synthesis of triacylglycerols in the liver 
[29]. Although there are no previous studies comparing the liver lipidome in NAFLD 
defined by HOMA-IR, the increase in the saturated and monounsaturated TAG 
species is consistent with previous data in common NAFLD. Lambert et al showed in 
groups of 13 subjects with a high and 13 subjects with a low liver fat content using 
multiple stable isotopes that DNL was 3-fold increased in subjects with high vs. low 
liver fat content [7]. DNL produces exclusively saturated fatty acids from substrates 
such as amino acids and simple sugars [29]. The other pathway that provides fatty 
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acids for intrahepatocellular triglycerols in NAFLD is adipose tissue lipolysis [30-32].
The increase in free saturated and monounsaturated fatty acids in the ’High HOMA-
IR’ vs. the ’Low HOMA-IR’ group could reflect either lipolysis or DNL. Since the 
human liver contains 2-fold more stearate (C18:0) and also significantly more 
palmitate (C16:0) than subcutaneous and intra-abdominal adipose tissue [33], the 
increase in saturated fatty acids likely predominantly reflects DNL.  
Of two major classes of bioactive lipids capable of inducing insulin resistance, we 
found virtually all ceramides to be significantly increased in ’Metabolic NAFLD’
(Fig. 4). In keeping with the increase in free palmitate (C16:0), the de novo ceramide 
synthetic pathway, as determined from the dihydroceramide concentrations, but not 
other ceramide synthetic pathways, was increased (Fig. 5). Formation of 
dihydroceramides is catalyzed by six different ceramide synthases (CerS1-6). CerS6
deficient mice exhibit reduced C16:0-ceramides such as Cer(d18:1/16:0) and are 
protected from high fat induced obesity, insulin resistance and adipose tissue 
inflammation [15]. A complementary paper showed that heterozygous CerS2
knockout mice, which are characterized by upregulation of C16:0-ceramides, display 
increased liver triglyceride and macrophage content, glucose intolerance and 
hyperinsulinemia [16].  The increases in the 16:0 and 18:0 dihydroceramides in the 
insulin-resistant human liver (Fig. 5) are entirely consistent with these recent mouse
data. 
Adiponectin regulates ceramide metabolism by upregulating ceramidase, the enzyme 
which which degrades ceramide to sphingosine [11]. Thus, adiponectin deficiency 
contributes to increased ceramide concentrations via impaired degradation. In the 
present study, the ‘High HOMA-IR’ group had lower serum adiponectin concetrations 
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than the ‘Low HOMA-IR’ group and there was a weak inverse correlation between 
serum adiponectin concentrations and ceramides in the liver. Adiponectin 
concentrations were similar in subjects with and without PNPLA3 I148M variant. 
Total hepatic DAGs have been previously shown to correlate with liver fat and fasting 
insulin/HOMA-IR in groups of 16 [9], 16 [34] and 37 [35] subjects. In the present 
study, 4 out of 5 DAGs, which are immediate precursors of TAGs, were increased in 
the ‘Metabolic NAFLD’. One DAG species was increased in the ‘PNPLA3 NAFLD’. 
The number of DAGs identified was low compared to the number of ceramides (Fig. 
4 vs. Supplementary Fig. 6) and it was not feasible to measure DAGs separately in 
subcellular compartments. Thus, the present data do not exclude the possibility that 
DAGs contribute to IR in the human liver. Along the same lines, even though the 
lipidome analyzed in the present study is the largest hitherto performed, there are 
other lipids which were not analyzed by the current platforms such as 
lysophosphatidic acid, phosphatidic acid, eicosanoids and endocannabinoids which 
may act as second messengers on key metabolic pathways [36]. 
Liver polyunsaturated TAGs were strikingly different between PNPLA3 variant allele 
carriers and non-carriers (Fig. 2). Kumari et al showed that human recombinant 
PNPLA3 I148M increases LPAAT activity from long unsaturated fatty acid 
containing CoAs such as arachnidonoyl and linoleoyl CoA much more than from 
saturated CoA [19]. The increase in polyunsaturated TAGs in the present study in the 
I148M variant allele carriers is thus compatible with these gain-of-function data as the 
increased TAGs in the ‘PNPLA3 NAFLD’ were long and highly unsaturated. The 
fold-increase in TAGs was particularly apparent in TAGs containing 5-8 double 
bonds (Fig. 2 and Supplementary Fig. 4). The increase in polyunsaturated DAGs in 
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the ‘PNPLA3 NAFLD’ is also compatible with the gain-of-function data. The lack of 
change in hepatic FFAs, which covered 80% of previously described all human liver 
FFAs and 87% of all free polyunsaturated fatty acids [37], supports the idea that the 
increase in polyunsaturated hepatic TAGs in ‘PNPLA3 NAFLD’ was driven by 
increased enzymatic activity rather than substrate availability.  
Few differences were observed in concentrations of saturated and monounsaturated 
TAGs between the PNPLA3 subgroups. In addition to LPAAT activity, the gene 
variant also inhibits lipolysis of TAGs containing especially monounsaturated fatty 
acids when overexpressed in the mouse liver [18]. This mechanism does not seem to 
explain the present data although it could have contributed to increases in 
monounsaturated fatty acids in the polyunsaturated TAGs.  
We are aware of one previous study, which characterized relative fatty acid profiles 
using thin layer chromatography between 19 subjects carrying the I148M variant 
allele carriers and 33 non-carriers undergoing liver surgery [38]. A relative reduction 
in stearic acid was found in keeping with the present data. However, the subjects were 
not characterized or analyzed with respect to features of insulin resistance or 
ceramides and TAGs by chain length and number.  
The subjects with ’Metabolic NAFLD’ and ’PNPLA3 NAFLD’ had an equal 
frequency of NASH (Table 1) despite very different hepatic triglyceride and bioactive 
lipid compositions. Previous studies have clearly established that the PNPLA3 gene 
variant prediposes to NASH independent of features insulin resistance [39]. Several 
possible mechanisms could increase the risk of NASH in carriers of the I148M gene 
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variant. PUFAs, once in TAGs, are metabolically inert and as such cannot contribute 
to NASH [40]. In the present study, which included measurement of liver FFA, the 
concentration of free unsaturated fatty acids were unchanged in PNPLA3 I148M 
variant allele carriers compared to non-carriers. We therefore cannot ascribe changes 
in liver histology to those in polyunsaturated fatty acids. Simple steatosis without 
hepatocellular injury has been recently shown to predict NASH [41]. In NASH, fat 
accumulates in the perivenous area in Zone 3 [26], which is characterized by impaired 
microcirculation and decreased oxygen concentrations [42]. Ballooning necrosis 
occurs in the midst of such fat-filled regions [26]. The PNPLA3 gene variant could 
therefore simply increase the risk of NAFLD by increasing steatosis. Histologically, 
PNPLA3 variant allele carriers have all features of NASH [43]. The PNPLA3 gene 
variant may also have effects outside hepatocytes in stellate cells [44] and 
extrahepatic tissues [45]. 
In conclusion, the present data show that insulin resistance in the human liver is 
associated with increased concentrations of saturated and monounsaturated FFAs and 
TAGs as well as ceramides from the de novo ceramide synthetic pathway. These data 
are consistent with several known pathophysiologic features of human ‘Metabolic 
NAFLD’. The human liver lipidome in ‘PNPLA3 NAFLD’ lacks all of these changes 
and is characterized by increased concentrations of polyunsaturated TAGs, which can 
be attributed to known functions of the I148M variant in in vitro studies [18,19]. Both 
types of NAFLD confer increased prevalence of NASH suggesting that increased 
concentrations of bioactive lipids are not necessary for development of NASH.
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Figure legends 
Fig. 1A. BMI (upper left panels), fasting insulin (upper right panels), liver fat (lower 
left panels) and adiponectin (lower right panels) between ‘Low HOMA-IR’ vs. ‘High 
HOMA-IR’ (panels on the left side of each comparison) and ‘PNPLA3148II’ vs. 
PNPLA3148MM/MI’ (panels on the right side of each comparison). Data are shown 
in mean ± SEM for BMI, and in medians and interquartile ranges for other variables. 
‘ns’ p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Fig. 1B. Plasma glucose and serum insulin during OGTT between ‘Low HOMA-IR’ 
vs. ‘High HOMA-IR’ (panels on the left side of each comparison) and 
‘PNPLA3148II’ vs. ‘PNPLA3148MM/MI’, panels on the right side of each 
comparison). Data are in means ± SEM. ‘ns’ p>0.05, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
Fig. 2. Absolute concentrations of hepatic TAGs between groups (‘High HOMA-IR’ 
vs. ‘Low HOMA-IR’, panel on the left; ‘PNPLA3148MM/MI’ vs. ‘PNPLA3148II’ 
groups panel on the right). The color code represents the log of the ratio between 
means of the groups for an individual TAG. The y-axes denote the number of carbons 
and the x-axes the number of double bonds. The brighter the red color, the greater 
increase of absolute concentration of the individual TAG in the ‘High HOMA-IR’ 
compared to the ‘Low HOMA-IR’ group or the PNPLA3148MM/MI’ compared to 
the ‘PNPLA3148II’ group. *p<0.05, **p<0.01, ***p<0.001.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
32 
Fig. 3. Absolute concentrations of hepatic FFAs between groups (‘High HOMA-IR’ 
vs. ‘Low HOMA-IR’, panel on the left;  ‘PNPLA3148MM/MI’ vs. ‘PNPLA3148II’ 
groups panel on the right). The y-axes denote the total concentration of free fatty 
acids. The segments in different color in each column represent individual FFAs. ‘ns’ 
p>0.05, *p<0.05. 
Fig. 4. Absolute concentrations of hepatic ceramides between groups (‘High HOMA-
IR’ vs. ‘Low HOMA-IR’, panel on the left; ‘PNPLA3148MM/MI’ vs. 
‘PNPLA3148II’ groups panel on the right). The top panel represents the structure of a 
ceramide. In the heatmaps, the color code indicates the log of the ratio between means 
of the groups for an individual ceramide. The y-axes denote the fatty acyl chain and 
the x-axes the sphingoid base species. The brighter the red color, the greater increase 
of absolute concentration of the individual ceramide in the ‘High HOMA-IR’ 
compared to the ‘Low HOMA-IR’ group or the PNPLA3148MM/MI’ compared to 
the ‘PNPLA3148II’ group. *p<0.05, **p<0.01, ***p<0.001.
Fig. 5. Pathways of ceramide synthesis. The schematic diagram (panel on the left) 
depicts the pathways of ceramide metabolism (14). Ceramides can be synthesized via 
the de novo synthetic pathway in which palmitate is metabolized to dihydroceramides 
prior to formation of ceramides (heatmap on the left). They can also be formed via the 
salvage pathway from hexosylceramides (middle heatmap) and via sphingomyelin 
hydrolysis (heatmap on the right). Ceramides are degraded by ceramidase, which is 
upregulated by adiponectin. In the heatmaps, the color code indicates the log of the 
ratio between means of the ’High’ vs. ’Low HOMA-IR’ groups for an individual 
lipid. The y-axes denote the fatty acyl chain and the x-axes the sphingoid base. The 
brighter the red color, the greater increase of absolute concentration of the individual
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lipid. *p<0.05, **p<0.01.
Table 1. Clinical characteristics of the study subjects according to HOMA-IR and the PNPLA3 genotype at 
rs738409. 
Total 
Low HOMA-IR  
(n=63) 
High HOMA-IR 
(n=62) 
PNPLA3
148II
(n=64) 
PNPLA3
148MM/MI
(n=61) 
Age (years) 49.2 ± 1.1 46.2 ± 1.1 46.2 ± 1.1 49.3 ± 1.0* 
Gender (n, % women) 45 (71.4) 38 (61.3) 45 (70.3) 38 (62.3) 
Waist circumference (cm) 127.6 ± 1.8 135.5 ± 1.6** 130.2 ± 1.8 132.9 ± 1.8 
fP-Glucose (mmol/l) 5.5 (4.7 - 6.0) 6.1 (5.6 – 6.8)**** 5.8 (5.2 - 6.4) 5.7 (5.3 - 6.5) 
HbA1C (%) 5.7 (5.5 - 6.1) 6.0 (5.6 - 6.5) 5.7 (5.5 - 6.3) 5.9 (5.5 - 6.3) 
HbA1C (mmol/mol) 38.8 (36.6 – 43.2) 42.1 (37.7 – 47.0) 38.8 (36.9 – 45.4) 41.0 (36.9 – 45.1) 
HOMA-IR 1.8 (1.3 – 2.7) 4.8 (3.9 – 5.8)**** 3.2 (1.9 - 4.5) 3.2 (1.7 - 5.1) 
Matsuda ISI 89.8 (65.7 – 141.9) 35.5 (27.3 – 45.1)**** 53.7 (35.0 – 87.8) 51.2 (34.3 – 96.8) 
fP-Triglycerides (mmol/l) 1.12 (0.91 - 1.66) 1.34 (1.15 - 1.85)* 1.29 (0.97 - 1.80) 1.26 (1.00 - 1.66) 
fP-HDL cholesterol (mmol/l) 1.17 (1.00 - 1.44) 1.02 (0.89 - 1.21)** 1.10 (0.95 - 1.36) 1.11 (0.95 - 1.30) 
fP-LDL cholesterol (mmol/l) 2.4 ± 0.1 2.5 ± 0.1 2.5 ± 0.1 2.4 ± 0.1 
Liver fat (%) 5 (0 - 20) 15 (5 - 33)** 5 (0 - 28) 15 (5 - 30)* 
P-AST (IU/l) 30 (25 - 37) 31 (26 - 38) 28 (24 - 33) 32 (26 - 41)** 
P-ALT (IU/l) 28 (22 - 40) 38 (30 - 51)**** 31 (24 - 45) 36 (27 - 46) 
P-ALP (IU/l) 65 ± 2 65 ± 2 66 ± 2 64 ± 2 
P-GGT (U/l) 26 (19 - 38) 36 (23 - 52)* 28 (20 - 44) 32 (22 - 52) 
P-Albumin (g/l) 37.6 (36.6 - 39.3) 38.0 (36.1 – 39.7) 37.8 (36.3 - 39.4) 37.9 (36.0 - 39.3) 
B-Platelets (x10
9
/l) 246 ± 9 252 ± 8 258 ± 9 240 ± 7 
PNPLA3 (CC/CG/GG) (n) 32/27/4 32/27/3 64/0/0 0/54/7**** 
Use of statins (n) 18  22 22 18 
NASH (%) 11.1 29.0*  12.5 27.9* 
Women/men with NASH (n) 4/3 9/9 4/4 9/8 
Data are in n (%), means ± SEM or median (25th-75th percentile), as appropriate. *P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001. 
****P ≤ 0.0001.   
Table
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
Supplementary material
Click here to download Supplementary material: Supplementary_material_051115_FINAL.docx
